Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riluzole for prevention of oxaliplatin-induced neurotoxicity in colorectal cancer
ACTRN12611000514909Phase 2Completed
- Sponsor
- Prince of Wales Hospital
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in colorectal cancer (CRC) and peripheral neuropathy (CIPN) comparing Riluzole plus oxaliplatin chemotherapy with Placebo plus oxaliplatin chemotherapy (2 arms). Primary endpoint: Reduction in chronic neuropathy and neuropathic symptoms. Started Jul 2011; status: completed.
02
Drugs
riluzole
03
Conditions
colorectal cancer (CRC)peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on ACTRN12611000514909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000514909.